Document Classification

Section Type: RESULTS

Text: Placebo treatment had no effect on glucose or inflammation, whereas troglitazone reduced fasting glucose (from 10. 4 + / -0. 6 mmol/l to 8. 1 + / -0. 5 mmol/l, p < 0. 01), HbA1c (from 8. 7 + / -0. 3 % to 7. 5 + / -0. 3 %, p < 0. 01), insulin requirements (from 75 + / -10 U/day to 63 + / -10 U/day, p < 0. 05), serum amyloid A (from 6. 3 + / -1. 5 mg/l to 4. 0 + / -1. 3 mg/l, p = 0. 001), alpha-1-acid glycoprotein (from 906 + / -51 mg/l to 729 + / -52 mg/l, p = 0. 001) and C3 (from 1. 72 + / -0. 07 g/l to 1. 66 + / -0. 06 g/l, p < 0. 05) but not alpha-1-antitrypsin, ceruloplasmin, C-reactive protein or haptoglobin significantly.